CoChat

Carrot RG-I Reduces Interindividual Differences between 24 Adults through Consistent Effects on Gut Microbiota Composition and Function Ex Vivo

Open access
Van den Abbeele, Pieter, Deyaert, Stef, Albers, Ruud, Baudot, Aurélien, Mercenier, Annick · 2023 · Nutrients

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Abstract

The human gut microbiota is characterized by large interpersonal differences, which are not only linked to health and disease but also determine the outcome of nutritional interventions. In line with the growing interest for developing targeted gut microbiota modulators, the selectivity of a carrot-derived rhamnogalacturonan I (cRG-I) was compared to substrates with demonstrated low (inulin, IN) and high selectivity (xanthan, XA), at a human equivalent dose (HED) of 1.5 g/d. The high throughput of the ex vivo SIFR® technology, validated to generate predictive insights for clinical findings, enabled the inclusion of 24 human adults. Such an unprecedented high number of samples in the context of in vitro gut microbiota modelling allowed a coverage of clinically relevant interpersonal differences in gut microbiota composition and function. A key finding was that cRG-I supplementation (already at an HED of 0.3 g/d) lowered interpersonal compositional differences due to the selective stimulation of taxa that were consistently present among human adults, including OTUs related to Bacteroides dorei/vulgatus and Bifidobacterium longum (suspected keystone species), Bacteroides thetaiotaomicron, Bifidobacterium adolescentis and butyrate-producing taxa such as Blautia sp., Anaerobutyricum hallii, and Faecalibacterium prausnitzii. In contrast, both IN and XA treatments increased interpersonal compositional differences. For IN, this followed from its low specificity. For XA, it was rather the extremely high selectivity of XA fermentation that caused large differences between 15 responders and 9 nonresponders, caused by the presence/absence of highly specific XA-fermenting taxa. While all test compounds significantly enhanced acetate, propionate, butyrate, and gas production, cRG-I resulted in a significantly higher acetate (+40%), propionate (+22%), yet a lower gas production (–44%) compared to IN. cRG-I could thus result in overall more robust beneficial effects, while also being better tolerated. Moreover, owing to its remarkable homogenization effect on microbial composition and metabolite production, cRG-I could lead to more predictable outcomes compared to substrates that are less specific or overly specific.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/nu15092090

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Study design using the ex vivo SIFR® technology to assess the selectivity by which cRG-I, IN, and XA affect the gut microbiota of 24 human adults that together covered clinically relevant interpersonal differences in microbiota composition. (A) Reactor design using the ex vivo SIFR® technology to test the impact of cRG-I, IN, and XA at an equivalent dose of 0.3 g/d (cRG-I_L) or 1.5 g/d (cRG-I_H, IN and XA), compared to a reference without additional substrate (NSC) in faecal samples of 24 human adults. (B) Schematic chemical structures of the different test products and (C) PCA biplot based on centred values of microbial families (%) at baseline (0 h), as part of the faecal microbiota for each of the 24 human adults. SIFR = systemic intestinal fermentation research; cRG-I = carrot-derived rhamnogalacturonan; IN = inulin; XA = xanthan; NSC = no-substrate control.
Figure 1 Study design using the ex vivo SIFR® technology to assess the selectivity by which cRG-I, IN, and XA affect the gut microbiota of 24 human adults that together covered clinically relevant interpersonal differences in microbiota composition. (A) Reactor design using the ex vivo SIFR® technology to test the impact of cRG-I, IN, and XA at an equivalent dose of 0.3 g/d (cRG-I_L) or 1.5 g/d (cRG-I_H, IN and XA), compared to a reference without additional substrate (NSC) in faecal samples of 24 human adults. (B) Schematic chemical structures of the different test products and (C) PCA biplot based on centred values of microbial families (%) at baseline (0 h), as part of the faecal microbiota for each of the 24 human adults. SIFR = systemic intestinal fermentation research; cRG-I = carrot-derived rhamnogalacturonan; IN = inulin; XA = xanthan; NSC = no-substrate control.CC BY · PubMed Central
Figure 2 High-dose cRG-I resulted in a marked and consistent bacterial cell density increase, along with decreases in β-diversity and pH. Impact on (A) bacterial density (cells/mL), (B) α-diversity (Chao1 diversity index), (C) β-diversity (weighted Unifrac index) and (D) pH by treatments with cRG-I, IN, and XA at an equivalent dose of 0.3 g/d (cRG-I_L) or 1.5 g/d (cRG-I_H, IN and XA), compared to an untreated reference (NSC) for human adults (n = 24), as tested with the ex vivo SIFR® technology. Statistical differences between treatments and NSC are indicated with asterisks (* (padjusted < 0.05), ** (padjusted < 0.01), or *** (padjusted < 0.001)). Further, differences between the low and high doses of cRG-I are indicated with $/$$/$$$, while differences among test compounds at an equivalent of 1.5 g/d are indicated with &/&&/&&&. SIFR = systemic intestinal fermentation research; cRG-I = carrot-derived rhamnogalacturonan; IN = inulin; XA = xanthan; NSC = no-substrate control.
Figure 2 High-dose cRG-I resulted in a marked and consistent bacterial cell density increase, along with decreases in β-diversity and pH. Impact on (A) bacterial density (cells/mL), (B) α-diversity (Chao1 diversity index), (C) β-diversity (weighted Unifrac index) and (D) pH by treatments with cRG-I, IN, and XA at an equivalent dose of 0.3 g/d (cRG-I_L) or 1.5 g/d (cRG-I_H, IN and XA), compared to an untreated reference (NSC) for human adults (n = 24), as tested with the ex vivo SIFR® technology. Statistical differences between treatments and NSC are indicated with asterisks (* (padjusted < 0.05), ** (padjusted < 0.01), or *** (padjusted < 0.001)). Further, differences between the low and high doses of cRG-I are indicated with $/$$/$$$, while differences among test compounds at an equivalent of 1.5 g/d are indicated with &/&&/&&&. SIFR = systemic intestinal fermentation research; cRG-I = carrot-derived rhamnogalacturonan; IN = inulin; XA = xanthan; NSC = no-substrate control.CC BY · PubMed Central
Figure 3 High-dose cRG-I exerted most consistent effects on gut microbial phyla and families. Impact on four most abundant phyla, i.e., (A) Actinobacteria, (B) Bacteroidetes, (C) Firmicutes, and (D) unclassified bacteria (cells/mL) at 48 h, upon supplementation with cRG-I, IN, and XA at an equivalent dose of 0.3 g/d (cRG-I_L) or 1.5 g/d (cRG-I_H, IN and XA), compared to an untreated reference (NSC) for human adults (n = 24), as tested with the ex vivo SIFR® technology. Statistical differences between treatments and NSC are indicated with asterisks (* (padjusted < 0.05), ** (padjusted < 0.01), or *** (padjusted < 0.001)). Further, statistical differences between the low and high doses of cRG-I are indicated with $/$$/$$$, while differences among test compounds at an equivalent of 1.5 g/d are indicated with &/&&/&&&. (E) Heatmap showing microbial families that were significantly affected by any of the treatments, expressed as log2(treatment/NSC). Significant differences were indicated by bold/underlining (FDR = 0.05). SIFR = systemic intestinal fermentation research; cRG-I = carrot-derived rhamnogalacturonan; IN = inulin; XA = xanthan; NSC = no-substrate control.
Figure 3 High-dose cRG-I exerted most consistent effects on gut microbial phyla and families. Impact on four most abundant phyla, i.e., (A) Actinobacteria, (B) Bacteroidetes, (C) Firmicutes, and (D) unclassified bacteria (cells/mL) at 48 h, upon supplementation with cRG-I, IN, and XA at an equivalent dose of 0.3 g/d (cRG-I_L) or 1.5 g/d (cRG-I_H, IN and XA), compared to an untreated reference (NSC) for human adults (n = 24), as tested with the ex vivo SIFR® technology. Statistical differences between treatments and NSC are indicated with asterisks (* (padjusted < 0.05), ** (padjusted < 0.01), or *** (padjusted < 0.001)). Further, statistical differences between the low and high doses of cRG-I are indicated with $/$$/$$$, while differences among test compounds at an equivalent of 1.5 g/d are indicated with &/&&/&&&. (E) Heatmap showing microbial families that were significantly affected by any of the treatments, expressed as log2(treatment/NSC). Significant differences were indicated by bold/underlining (FDR = 0.05). SIFR = systemic intestinal fermentation research; cRG-I = carrot-derived rhamnogalacturonan; IN = inulin; XA = xanthan; NSC = no-substrate control.CC BY · PubMed Central
Figure 4 High-dose cRG-I markedly and consistently increased OTUs related to Bacteroides dorei/vulgatus and Bifidobacterium longum. PCA biplot based on centred values of OTUs (cells/mL) along with dedicated violin plots for OTUs determining the sample distribution at 48 h, upon supplementation with cRG-I, IN, and XA at an equivalent dose of 0.3 g/d (cRG-I_L) or 1.5 g/d (cRG-I_H, IN and XA), compared to an untreated reference (NSC) for human adults (n = 24), as tested with the ex vivo SIFR® technology. Statistical differences between treatments and NSC are indicated with asterisks (* (padjusted < 0.05), ** (padjusted < 0.01), or *** (padjusted < 0.001)). Further, statistical differences between the low and high doses of cRG-I are indicated with $/$$/$$$, while differences among test compounds at an equivalent of 1.5 g/d are indicated with &/&&/&&&. OTU = operational taxonomic unit; PCA = principal component analysis; cRG-I = carrot-derived rhamnogalacturonan; IN = inulin; XA = xanthan; XAR = XA responders, XANR = XA nonresponders; NSC = no-substrate control; SIFR = systemic intestinal fermentation research.
Figure 4 High-dose cRG-I markedly and consistently increased OTUs related to Bacteroides dorei/vulgatus and Bifidobacterium longum. PCA biplot based on centred values of OTUs (cells/mL) along with dedicated violin plots for OTUs determining the sample distribution at 48 h, upon supplementation with cRG-I, IN, and XA at an equivalent dose of 0.3 g/d (cRG-I_L) or 1.5 g/d (cRG-I_H, IN and XA), compared to an untreated reference (NSC) for human adults (n = 24), as tested with the ex vivo SIFR® technology. Statistical differences between treatments and NSC are indicated with asterisks (* (padjusted < 0.05), ** (padjusted < 0.01), or *** (padjusted < 0.001)). Further, statistical differences between the low and high doses of cRG-I are indicated with $/$$/$$$, while differences among test compounds at an equivalent of 1.5 g/d are indicated with &/&&/&&&. OTU = operational taxonomic unit; PCA = principal component analysis; cRG-I = carrot-derived rhamnogalacturonan; IN = inulin; XA = xanthan; XAR = XA responders, XANR = XA nonresponders; NSC = no-substrate control; SIFR = systemic intestinal fermentation research.CC BY · PubMed Central
Figure 5 High-dose cRG-I most strongly increased total SCFA due to a marked increase of acetate and propionate, with relatively small increases of gas production. (A) PCA biplot based on standardized values of SCFA (mM) along with dedicated violin plots for (B) acetate, (C) propionate, (D) butyrate, (E) bCFA, (F) total SCFA, and (G) gas production (mbar) at 48 h, upon supplementation with cRG-I, IN, and XA at an equivalent dose of 0.3 g/d (cRG-I_L) or 1.5 g/d (cRG-I_H, IN and XA), compared to an untreated reference (NSC) for human adults (n = 24), as tested with the ex vivo SIFR® technology. Statistical differences between treatments and NSC are indicated with asterisks (* (padjusted < 0.05), ** (padjusted < 0.01), or *** (padjusted < 0.001)). Further, statistical differences between the low and high doses of cRG-I are indicated with $/$$/$$$, while differences among test compounds at an equivalent of 1.5 g/d are indicated with &/&&/&&&. SCFA = short-chain fatty acids; PCA = principal component analysis; cRG-I = carrot-derived rhamnogalacturonan; IN = inulin; XA = xanthan; NSC = no-substrate control; SIFR = systemic intestinal fermentation research.
Figure 5 High-dose cRG-I most strongly increased total SCFA due to a marked increase of acetate and propionate, with relatively small increases of gas production. (A) PCA biplot based on standardized values of SCFA (mM) along with dedicated violin plots for (B) acetate, (C) propionate, (D) butyrate, (E) bCFA, (F) total SCFA, and (G) gas production (mbar) at 48 h, upon supplementation with cRG-I, IN, and XA at an equivalent dose of 0.3 g/d (cRG-I_L) or 1.5 g/d (cRG-I_H, IN and XA), compared to an untreated reference (NSC) for human adults (n = 24), as tested with the ex vivo SIFR® technology. Statistical differences between treatments and NSC are indicated with asterisks (* (padjusted < 0.05), ** (padjusted < 0.01), or *** (padjusted < 0.001)). Further, statistical differences between the low and high doses of cRG-I are indicated with $/$$/$$$, while differences among test compounds at an equivalent of 1.5 g/d are indicated with &/&&/&&&. SCFA = short-chain fatty acids; PCA = principal component analysis; cRG-I = carrot-derived rhamnogalacturonan; IN = inulin; XA = xanthan; NSC = no-substrate control; SIFR = systemic intestinal fermentation research.CC BY · PubMed Central
Figure 6 High-dose cRG-I exerted consistent stimulatory effects on a range of OTUs, which resulted in marked correlations between specific fundamental fermentation parameters and these OTUs. Heatmap showing correlations based on a rCCA between fermentation parameters (pH, gas production, and SCFA) and OTUs that were significantly affected (FDR = 0.05) by any of the treatments, i.e., (A) cRG-I_L, (B) cRG-I_H, (C) XA, and (D) IN for human adults (n = 24), as tested with the ex vivo SIFR® technology. The OTUs that were significantly increased by a given treatment are preceded by an asterisk in the plot of this treatment. OTU = operational taxonomic unit; rCCA = regularized canonical correlation analysis; SCFA = short-chain fatty acids; cRG-I = carrot-derived rhamnogalacturonan; IN = inulin; XA = xanthan; SIFR = systemic intestinal fermentation research.
Figure 6 High-dose cRG-I exerted consistent stimulatory effects on a range of OTUs, which resulted in marked correlations between specific fundamental fermentation parameters and these OTUs. Heatmap showing correlations based on a rCCA between fermentation parameters (pH, gas production, and SCFA) and OTUs that were significantly affected (FDR = 0.05) by any of the treatments, i.e., (A) cRG-I_L, (B) cRG-I_H, (C) XA, and (D) IN for human adults (n = 24), as tested with the ex vivo SIFR® technology. The OTUs that were significantly increased by a given treatment are preceded by an asterisk in the plot of this treatment. OTU = operational taxonomic unit; rCCA = regularized canonical correlation analysis; SCFA = short-chain fatty acids; cRG-I = carrot-derived rhamnogalacturonan; IN = inulin; XA = xanthan; SIFR = systemic intestinal fermentation research.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Cited by

Metadata

Authors
Van den Abbeele, P., Deyaert, S., Albers, R., Baudot, A., & Mercenier, A.
Affiliations
  • Cryptobiotix SA, 9052 Ghent, Belgium
  • NutriLeads (Netherlands) (NL)
Corresponding author
Mercenier, Annick
Venue
Nutrients
Publisher
MDPI AG
Published
2023-04-26
Volume
15
Issue
9
Pages
2090
ISSN
2072-6643 (ISSN-L)
OpenAlex
W4367183657
Cited by
46
References
68
Citations by year
2026: 16 · 2025: 17 · 2024: 10 · 2023: 3
FWCI
4.09
Type
journal article
Language
en
Open access
Locations
  • Nutrients (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
NutriLeads B.V., Wageningen, The Netherlands
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Nursing › Nutrition and Dietetics › Microbial Metabolites in Food Biotechnology
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
Keywords
rhamnogalacturonan I, carrot, gut microbiota, interpersonal variability, prebiotics, inulin, xanthan gum, butyrate production, short-chain fatty acids, acetate, propionate, Bacteroides, Bifidobacterium, Faecalibacterium prausnitzii
MeSH terms
Gastrointestinal Microbiome, Adult, Bacteroides, Butyrates, Humans, Propionates, Daucus carota

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.